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Imbalance in the expression of 
Genes Associated with purinergic 
signalling in the Lung and systemic 
Arteries of CopD patients
oriol Careta1,2,3, Ester Cuevas  1,2,3, Mariana Muñoz-Esquerre1,2,3, Marta López-Sánchez1,2,3, 
Yuliana pascual-González1,2,3, Jordi Dorca1,2,3, Elisabet Aliagas1,2,3 & salud santos1,2,3,4
Growing evidence indicates that purinergic signalling is involved in the pathogenesis of chronic 
obstructive pulmonary disease (CopD) and in the vascular remodelling that occurs in other disorders; 
however, its role in initial vascular changes of COPD is not entirely known. We hypothesised that 
expression of genes regulating extracellular Atp and adenosine levels would be altered in the lung and 
systemic arteries of COPD patients. Quantitative real-time PCR was performed to analyse the relative 
expression of 17 genes associated with purinergic signalling and inflammation in lungs and intercostal 
arteries of never smokers (NS) (n = 16), non-obstructed smokers (NOS) (n = 17) and COPD patients 
(n = 21). Gene expression of ATP-degrading enzymes was decreased in both tissues of NOS and COPD 
patients compared to NS. NT5E expression (gene transcribing for an AMP hydrolyzing ectonucleotidase) 
was increased in both tissues in NOS compared to the other groups. P1 and P2 receptors did not 
show changes in expression. Expression of genes associated with inflammation (interleukin-13) was 
upregulated only in lung tissues of COPD. These findings suggest that the expression of different 
extracellular ATP-degrading enzymes is altered in smokers (NOS and COPD patients), promoting 
inflammation. However, the high NT5E expression found only in NOS could compensate this 
inflammatory environment.
Chronic obstructive pulmonary disease (COPD) is a highly prevalent chronic respiratory disease and a major 
cause of mortality and morbidity worldwide1. Smoking has long been recognised as the main risk factor2, but not 
all smokers develop the disease. The factors that determine the development of COPD in susceptible smokers 
are complex and may involve genetic and epigenetic factors, altered immune regulation, and abnormal repair 
mechanisms3,4.
COPD is associated with vascular alterations in both pulmonary and systemic arteries5. In advanced stages of 
the disease, the risk of developing pulmonary hypertension increases due to the loss of pulmonary vessels caused 
by emphysema, pulmonary vascular remodelling, and chronic hypoxaemia6. However, in the pulmonary arteries 
of patients with moderate COPD, an association between endothelial dysfunction6, structural changes7, and the 
presence of an inflammatory infiltrate in the adventitial layer8 has been also described.
Recently, morphometric studies carried out on the systemic and pulmonary arteries of patients with 
mild-moderate COPD have demonstrated a significant correlation between the initial changes that occur in the 
walls of both systemic and pulmonary arteries. These systemic and pulmonary changes are characterised by a 
thickening of the intima and a decrease in the vascular lumen, which are observed to a greater degree in COPD 
patients than in smokers without airflow obstruction9. To date, the mediators involved in these processes are not 
well known.
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Numerous studies have indicated that purinergic signalling plays a major role in the development of COPD10–12  
and in the vascular remodelling that occurs in other disorders like idiopathic pulmonary fibrosis13. Purinergic 
signalling involves purines (ATP and its hydrolysis products) and pyrimidines (mainly UTP) that act as extracel-
lular ligands for the widely-expressed purinergic receptors, P2 (activated by nucleoside tri-/diphosphates among 
others) and P1 (activated by adenosine and others)14. It is well known that ATP and adenosine levels are increased 
in the lungs of COPD patients15,16, which could be associated with COPD development. Extracellular levels of 
ATP and adenosine are controlled by membrane proteins called ectonucleotidases, which include four families: 
the ectonucleoside triphosphate diphosphohydrolase (ENTPDase) family, the ectonucleotide pyrophosphatase/
phosphodiesterase (ENPP) family, the alkaline phosphatase (AP) family, and the 5′-nucleotidase family, of which 
only one member (NT5E/CD73) is expressed on the membrane17.
The present study explored the expression of the genes involved in purinergic signalling and inflammation in 
the lung and vascular systemic tissues of never smokers (NS), non-obstructed smokers (NOS) and stable COPD 
patients. We performed quantitative real-time PCR on peripheral lung tissue and intercostal arteries (represent-
ative systemic vascular tissue) to examine the expression of 17 genes of interest.
Results
Gene expression studies in the lungs of NOS and COPD patients compared to NS. Gene expres-
sion of ATP-degrading enzymes and DPP4. The gene expression of ATP-degrading enzymes and DPP4, which 
binds adenosine deaminase (ADA), is shown in Fig. 1A. All the ATP-degrading enzymes studied (ENTPD1, 
ENTPD2 and ENTPD3) showed a similar expression pattern in both NOS and COPD patients, with decreases 
in ENTPD1 and ENTPD2 expression and no changes in ENTPD3 expression. ENPP1 expression was upregu-
lated, while the gene expression of the adenosine-producing enzyme NT5E/CD73 was up to one-fold higher in 
NOS, but unchanged in COPD patients. ADA and DPP4 expression was downregulated in both NOS and COPD 
patients.
Gene expression of P1 and P2 receptors. The gene expression of the purinergic P1 and P2 receptors is shown in 
Fig. 1B. In the lungs of NOS and COPD patients, gene expression of all the ATP receptors studied (P2RX2, P2RX7 
and P2RY2) was downregulated. In the case of adenosine receptors, ADORA1 expression was downregulated 
only in COPD patients, while ADORA3 expression was upregulated in both groups. ADORA2A and ADORA2B 
expression in NOS and COPD patients was similar to that in NS.
Expression of the genes associated with inflammation. Among the three genes encoding inflammatory mole-
cules (IL-13, IL-4 and CCL18) that were analysed in pulmonary tissue (Fig. 1C), only IL-13 expression showed 
significant changes, as expected, with increases observed in both NOS and COPD patients. IL-4 expression was 
not amplified probably due to the lack of tissue expression. CCL18 expression was decreased in NOS and COPD 
patients compared to NS.
Gene expression studies in the intercostal arteries of NOS and COPD patients compared 
to NS. Gene expression of ATP-degrading enzymes and DPP4. Similar patterns of gene expression of the 
ATP-degrading enzymes were found in the intercostal arteries compared to pulmonary tissue (Fig. 2A). ENTPD1, 
ENTPD2 and ENTPD3 expression was downregulated in NOS, while ENTPD2 and ENTPD3 expression was also 
reduced in COPD patients. As observed in the lung samples, ENPP1 expression was upregulated in the intercostal 
arteries of both NOS and COPD patients. NT5E expression in the intercostal arteries was upregulated in NOS, as 
also seen in the lung tissue, but was reduced by up to one-fold in the intercostal arteries of COPD patients, which 
differed to that observed in the lungs. ADA and DPP4 expression was upregulated in the intercostal arteries of 
both groups, which was opposite to that observed in the lungs.
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Figure 1. Gene expression analyses in the lung. Changes in the mRNA expression of genes for: NOS vs. NS 
and COPD vs. NS. Results are expressed as fold change (log2) relative to NS. Bar plots represent median ± log2 
of RQmax and log2 of RQmin. (A) The expression of ENTPD1, ENTPD2, ADA and DPP4 was downregulated 
in NOS and COPD patients. ENPP1 expression was upregulated in NOS and COPD patients while NT5E 
expression was upregulated in NOS and unchanged in COPD. No changes were found in ENTPD3 expression. 
(B) P2RX2, P2RX7 and P2RY2 expression was downregulated in COPD patients and NOS as well as the 
expression of ADORA1 in COPD patients. ADORA2A and ADORA2B expression levels were similar to NS 
in both groups. ADORA3 expression in NOS and COPD patients along with ADORA2A expression in COPD 
patients was upregulated. No changes were found in ADORA1 expression in NOS. (C) IL-13 expression was 
upregulated whereas CCL18 expression was downregulated in NOS and COPD patients. No expression of IL-4 
was found. *Significantly different from NS (p < 0.05).
3Scientific RepoRts |          (2019) 9:2796  | https://doi.org/10.1038/s41598-019-39233-y
www.nature.com/scientificreportswww.nature.com/scientificreports/
Gene expression of P1 and P2 receptors. The expression patterns of the P1 and P2 receptors differed between the 
intercostal arteries and pulmonary tissue (Fig. 2B). In the intercostal arteries, P2RX2 expression was upregulated 
in COPD patients and downregulated in NOS (P2RX2 expression was downregulated in the lung tissues of both 
groups). P2RX7 expression also differed between the tissues in both groups. Unlike in lung tissue, P2RY2 expres-
sion was upregulated in the intercostal arteries of both groups. Whereas ADORA1 expression was downregulated 
in the lung samples of COPD patients, it was upregulated by up to one-fold in the intercostal arteries of both 
groups, this being significant for the COPD patients when compared to NS. There were no major differences in 
the expression levels of ADORA2A, ADORA2B and ADORA3 between the tissues.
Expression of the genes associated with inflammation. IL-13 and IL-4 expression was not amplified in the inter-
costal arteries, probably due to a lack of expression in these tissues (Fig. 2C). In NOS, CCL18 expression differed 
between the intercostal arteries and lung tissue, being upregulated by up to one-fold in the intercostal arteries 
(Fig. 2C).
Figure 3 summarises the main and most interesting results in the format of a heat map. To facilitate the under-
standing of our findings regarding the enzymes associated with purinergic signalling and their relationship with 
inflammation, we have highlighted the genes that promote or reduce inflammation.
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Figure 2. Gene expression studies in the intercostal arteries. Changes in the mRNA expression of genes for: 
NOS vs. NS and COPD vs. NS. Results are expressed as fold change (log2) relative to NS. Bar plots represent 
median ± log2 of RQmax and log2 of RQmin. (A) ENTPD2 and ENTPD3 expression was downregulated in 
NOS and COPD patients, as well as ENTPD1 in NOS and NT5E in COPD patients. ENPP1, ADA and DPP4 
expression levels were increased in both groups. ENTPD1 expression in COPD patients and NT5E expression 
in NOS were also upregulated. (B) P2RX2, ADORA2A and ADORA2B expression was downregulated in NOS. 
P2RX7 expression was also downregulated in both groups. P2RY2, ADORA1 and ADORA3 expression in NOS 
and COPD patients and P2RX2 and ADORA2B expression in COPD patients were also upregulated. No changes 
were found in ADORA2A expression in COPD patients. (C) No expression of IL-13 or IL-4 was found. CCL18 
expression was upregulated in NOS and downregulated in COPD patients. *Significantly different from NS 
(p < 0.05).
Figure 3. Schematic of the genes associated with purinergic signalling that were analysed. Heat map of the 
genes over- or underexpressed (log2 of RQ) in NOS and COPD patients compared to NS. Genes that promote or 
reduce inflammation are highlighted (red for promotion and green for reduction).
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No significant differences were found in the expression of the purinergic pathway genes in lung or intercostal 
artery after adjusting for sex and diabetes. Furthermore, to analyse potential susceptibility according to gender, 
independently of tobacco consumption, we compared the gene expression specifically in the non-smoker group 
and found no significant differences (p > 0.05) in the expression of purinergic pathway genes.
Comparison of gene expression levels in the lung and intercostal arteries between CopD 
patients and NOS. Changes in the gene expression levels in pulmonary tissue and intercostal arteries in 
COPD patients compared to NOS are shown in Table 1. All the ATP-degrading enzymes studied were downreg-
ulated in the lung, but upregulated or unaffected in the intercostal arteries of COPD patients compared to NOS. 
NT5E expression was downregulated in both tissues, while ADA expression was upregulated in the lung and 
downregulated in the intercostal arteries.
In the lung, P2RX2, P2RX7, ADORA1 and ADORA3 expression levels were downregulated, while P2RY2, 
ADORA2A and ADORA2B expression was upregulated. In the intercostal arteries, all the genes for the P1 and P2 
receptors, except ADORA3, were upregulated. Regarding the genes associated with inflammation, IL-13 expres-
sion was upregulated in pulmonary tissue, but not expressed in the intercostal arteries. IL-4 expression was not 
observed in the lung or intercostal arteries. CCL18 expression was downregulated in both tissues.
Discussion
The focus of our study was to characterise the expression patterns of the genes associated with purinergic sig-
nalling in the early phases of COPD. We also compared gene expression between pulmonary tissue and systemic 
arteries from the same patients to identify the mechanisms that initiate and perpetuate this disease and detect 
any potential molecules involved with the systemic vascular changes observed in COPD. This is the first study 
to explore the expression of the genes associated with purinergic signalling in the lung and systemic arteries of 
COPD patients using TaqMan low-density arrays.
Our results suggest that the downregulation of ATP-degrading and adenosine-producing enzymes in the lung 
and intercostal arteries could produce a pro-inflammatory state in COPD patients compared to NOS. Although 
ATP-degrading enzymes are also downregulated in both tissues in NOS, adenosine-generating enzymes are 
upregulated (Figs 1A and 2A), suggesting a compensatory mechanism that exists only in NOS. We found an 
imbalance between the enzymes regulating extracellular ATP and adenosine levels in the early stages of COPD 
that favoured ATP accumulation (acting as a pro-inflammatory molecule through the P2 receptors) and lowered 
adenosine levels (acting as anti-inflammatory molecules through the P1 receptors), possibly causing the overall 
pulmonary inflammation18. This imbalance could be overcome in NOS by an enhanced expression of NT5E, 
which encodes the main enzyme (CD73) regulating extracellular adenosine levels. Figure 4 summarizes all this 
information and represents the possible molecular mechanism in which changes in the expression of purinergic 
signalling genes favour the accumulation of extracellular ATP that may promote inflammation in COPD patients. 
Pulmonary tissue
p-value
IC arteries
p-valueFold change (log2) Fold change (log2)
Membrane purinergic degrading enzymes
ENTPD1/CD39 −0.366 0.458 0.332 0.608
ENTPD2 −0.129 0.861 0.116 0.902
ENTPD3 −0.009 0.987 0.253 0.627
ENPP1 −0.295 0.705 −0.032 0.906
NT5E/CD73 −0.671 0.386 −1.561 0.139
Soluble purinergic degrading enzyme
ADA 0.472 0.330 −0.268 0.595
ADA receptor
DPP4/CD26 −0.103 0.850 −0.137 0.745
P2 receptors
P2RX2 −0.597 0.288 0.938 0.404
P2RX7 −0.472 0.461 0.093 0.884
P2RY2 0.374 0.366 0.010 0.983
P1 receptors
ADORA1 −0.881 0.136 0.366 0.702
ADORA2A 0.429 0.129 0.471 0.487
ADORA2B 0.452 0.314 0.397 0.818
ADORA3 −0.211 0.739 −0.056 0.920
Inflammatory genes
IL-13 0.684 0.356 — —
IL-4 — — — —
CCL18 −0.474 0.539 −1.365 0.121
Table 1. Changes in gene expression in COPD patients compared to NOS.
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By contrast, NOS balanced the levels of extracellular pro-and anti-inflammatory molecules through the increase 
of NT5E/CD73 expression.
Previous studies have shown that tobacco induces an accumulation of extracellular ATP in the human res-
piratory tract, leading to high ATP concentrations in COPD patients, even after smoking cessation19. By acti-
vating P2 receptors, ATP induces macrophages and neutrophils to secrete pro-inflammatory molecules and 
the mediators of tissue degradation, thus contributing to the chronic inflammation characteristic of COPD15. 
Extracellular adenosine levels are also increased in the lungs of patients with severe COPD. In accordance with 
this, previous studies have shown that the enzymatic activity of NT5E/CD73 is increased in the lung tissue of 
patients with severe COPD compared to smokers with mild obstruction20. In addition, COPD patients with acute 
exacerbations have decreased ADA enzymatic activity (inactivates adenosine), thus favouring its extracellular 
accumulation21. Adenosine has immunomodulatory functions; thus, its role may be important in COPD. In fact, 
adenosine receptors have been proposed as possible therapeutic targets in the treatment of COPD22. However, 
all the studies to date have focused on the advanced stages of the disease (GOLD stages III and IV) to assess the 
roles of ATP and adenosine in the pathophysiology of COPD. Given the dual role of adenosine depending on the 
situation, i.e., acting as an anti-inflammatory molecule in processes associated with acute lung diseases23,24 or as a 
pro-inflammatory agent with tissue remodeling functions in chronic lung diseases25, it is important to distinguish 
between the early and late stages of COPD when determining the role of adenosine in this disease. Furthermore, 
some adenosine receptors also act as anti- or pro-inflammatory molecules depending on the stages (acute or 
chronic) of lung injury during which they are activated26.
As seen in Fig. 3, NOS expressed more genes favouring a non-inflammatory state than COPD patients in both 
pulmonary and systemic tissues when compared to NS. The downregulated ectonucleotidases play a larger role in 
inflammation secondary to tobacco in the lung than in the arterial tissue of the same patients. This observation 
is in line with the previous studies of our group demonstrating an underexpression of ENTPDase1/CD39 in 
the lungs of COPD patients27. NT5E/CD73, which is expressed less in the lungs of COPD patients than NOS, is 
Figure 4. Graphic image representation of the possible mechanisms of lung inflammation in COPD involving 
purinergic signaling pathway. See text for details and further information (second paragraph of the discussion 
section). Pro-inflammatory molecules: ATP and derivates (dark and light blue and pink circles). Anti-
inflammatory molecules: adenosine (yellow square). The figure was created using Servier Medical Art according 
to a Creative Commons Attribution 3.0 Unported License guidelines 3.0 (https://creativecommons.org/licenses/
by/3.0/). Simplification and colour changes were made to the original cartoons.
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markedly decreased in systemic arteries. NT5E/CD73 has been reported to play an important anti-inflammatory 
role that is associated with anti-fibrotic activity and a reduced production of pro-inflammatory cytokines in the 
aortic artery, most likely by activating adenosine A2a receptors28. This would be interesting to investigate further 
in future studies assessing the role of CD73 in cardiovascular risk.
Classically, the inflammation leading to COPD has been described as a type I inflammation predominantly 
involving neutrophils. In line with this, the inflammatory parameters analysed in our patients, such as C-reactive 
protein (CRP) and leukocyte blood counts, were higher in COPD patients than NOS, even though these dif-
ferences were not significant (Table 2). However, new evidence has emerged that type 2 or eosinophilic inflam-
mation also plays a role in some COPD patients29,30. For this reason, we decided to analyse both IL-13 and IL-4 
gene expression as they are involved in eosinophilic inflammation. Our results on IL-13 expression in lung tis-
sue provide a plausible explanation for why NOS show less inflammation than patients with moderate COPD 
(Fig. 1C). We analysed IL-4 and IL-13 expression to determine the type of inflammatory response elicited in our 
COPD patients. IL-13 expression was significantly elevated in the pulmonary tissues of NOS and COPD patients, 
suggesting a Th2-derived inflammatory response (Fig. 1C). IL-13 was not expressed in the intercostal arteries of 
NOS or COPD patients, suggesting that this type of inflammation is not relevant in the initial systemic vascular 
changes in smokers and patients with moderate COPD. As for IL-4, we could not assess any amplification of this 
gene in the lung or intercostal arteries (Figs 1C and 2C). We were not able to determine if this was because there 
was no expression or whether this was due to methodological issues. CCL18, a chemokine involved in vascular 
changes31, showed reduced expression in the lungs and systemic arteries of COPD patients. Other studies have 
shown a similar gene expression pattern of CCL18 in COPD patients and smokers31.
There were differences in purinergic signalling between patients with moderate COPD and NOS. However, other 
studies have found some similarities in the expression profiles of other genes between patients with moderate COPD 
and NOS, which have not been observed in patients with severe COPD32. For this reason, we believe that this study 
should be complemented with future studies investigating pulmonary levels of ATP and adenosine and the genetic 
expression of purinergic signalling enzymes in patients with severe COPD (GOLD stages III and IV) too.
This study had several strengths and limitations. Performing a genetic analysis on patients in the early stages 
of COPD enabled us to check for disease-initiating mechanisms that are more difficult to detect at later stages 
of the disease. Nevertheless, it has to be pointed out that this is an exploratory study to generate new hypotheses 
about the pathophysiological changes that occur in the first steps of COPD. Almost none of the p-values of the 
results comparing gene expression levels between the groups were statistically significant, probably because of 
the exploratory nature of the study and/or the small number of patients included. The study population had pri-
mary treatable lung cancer and, therefore, lung cancer could have been a possible introduced bias. However, we 
assumed that any bias introduced would have been the same for all the subjects. Moreover, this was the only way 
of obtaining fresh tissue samples from the patients along with clinical and functional data.
In summary, this preliminary study suggests that the expression patterns of different extracellular 
ATP-degrading enzymes are altered in a manner that promotes inflammation in both NOS and patients with early 
COPD, with a compensatory mechanism possibly occurring only in NOS. ENTPD1, ENTPD2 and NT5E might be 
relevant in the pathophysiology of COPD. Future studies are needed to confirm this hypothesis.
Parameters NS (n = 16) NOS (n = 17)
COPD (n = 21)  
GOLD I/II/III: 14/5/2 p-value
Gender, female/male 11/5 0/17 2/19 <0.0001
Age, years 61.7 ± 12.1 61.6 ± 11.1 62.8 ± 8.5 0.928
BMI, kg/m² 27 ± 4.2 27.8 ± 4.4 25.7 ± 4.6 0.342
Smoking history, pack/years — 38.9 ± 4.4 48 ± 3.5 0.113
Current smokers, n (%) — 9 (52.9) 5 (23.8) 0.067
HTA, n (%) 4 (25) 8 (47.1) 9 (42.9) 0.384
DLP, n (%) 8 (50) 9 (52.9) 11(52.4) 0.984
DM, n (%) 0 (0) 8 (47) 1 (4.8) <0.0001
FVC, % predicted 113.8 ± 21 99.4 ± 16.6 89.8 ± 14.1 <0.001
FEV1, % predicted 110.1 ± 20.3 95.4 ± 14.5 67 ± 15.7 <0.001
FEV1/FVC, % 77.4 ± 5.6 76 ± 5.1 56.2 ± 11.4 <0.001
DLCO, % predicted 93.6 ± 18 87.2 ± 17.3 69.5 ± 14.7 <0.001
Fibrinogen, g/L 3.1 ± 1.3 3.2 ± 1 3.2 ± 0.9 0.937
Leukocytes, cells/mm³ 6.8 ± 1.5 8.3 ± 1.9 8.7 ± 1.8 <0.05
Eosinophils, cells/mm3 134.4 ± 54 84.1 ± 42.7 116.2 ± 73 0.056
CRP, mg/L 3.6 ± 5 6.8 ± 10.2 8 ± 11.2 0.463
Cholesterol, mmol/L 4.7 ± 1 4.4 ± 0.8 4.5 ± 0.9 0.582
Table 2. Clinical parameters and lung function measurements of the subjects. Data are presented as mean ± SD. 
BMI, body mass index; HTA, arterial hypertension; DLP, dyslipidaemia; DM, diabetes mellitus; FVC, forced 
vital capacity; FEV1, forced expiratory volume in first second; DLCO, diffusing capacity for carbon monoxide; 
CRP, C-reactive protein.
7Scientific RepoRts |          (2019) 9:2796  | https://doi.org/10.1038/s41598-019-39233-y
www.nature.com/scientificreportswww.nature.com/scientificreports/
Materials and Methods
Subjects. Fifty-four patients who underwent a lobectomy or pneumonectomy of a solitary pulmonary nodule 
at Bellvitge University Hospital were included in this study. Demographic, clinical and pre-operative pulmonary 
function assessment (spirometry, lung volumes and carbon monoxide diffusing capacity) data were collected for all 
the subjects before surgery. None of the patients presented severe systemic comorbidities, atelectasis or obstructive 
pneumonitis. Moreover, they had not received chemotherapy or radiotherapy prior to surgery. According to their 
previous smoking history and the results of the pulmonary function tests, subjects were classified as follows: 16 
never smokers (NS), 17 non-obstructed smokers (NOS) and 21 stable COPD patients. COPD was diagnosed based 
on current GOLD guidelines33. In the COPD group, most of the patients had early stages of disease (14 GOLD I 
and five GOLD II). All the participants signed an informed consent in accordance with the principles outlined in 
the Declaration of Helsinki. The study was approved by the local ethics committee (CEIC, ref. PR330/15). General 
characteristics and lung function measurements of the three groups are summarised in Table 2.
Sample collection and processing. The samples used in this study were obtained and processed as previ-
ously described9. They have been used in previous studies published by our research group9,27,31.
RNA processing. Total RNA was isolated and purified as previously described27,31.
TaqMan low-density arrays. Gene expression analysis was performed by real-time PCR using Custom 
TaqMan low-density arrays (TLDAs; Applied Biosystems, Foster City, CA, USA). The 17 genes analysed in this 
study are listed in Table 3, classified by their functional groups. One µg of total RNA was retrotranscribed into 
cDNA using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Before performing PCR, 
cDNA was pre-amplified using Custom TaqMan PreAmp Pools, following the manufacturer’s protocol (Applied 
Biosystems). PCR reactions were prepared with the TaqMan Gene Expression Master Mix, following the manu-
facturer’s protocol (Applied Biosystems), and samples were run in triplicate on an ABI Prism 7900HT Real-Time 
PCR System (Applied Biosystems). Data were collected using SDS Software version 2.4 (Applied Biosystems) and 
used for subsequent analysis.
Gene expression analysis. Data analysis was performed using the Relative Quantification applica-
tion module on the Thermo Fisher Cloud online software (https://www.thermofisher.com/es/es/home/cloud.
html). Relative quantification (RQ) was based on the comparative cycle threshold (Ct) method using GAPDH 
(Hs99999905_m1) as an endogenous control. For differential expression analysis, a limma-modified t-test34 was 
used to calculate the ΔΔCt value [ΔΔCt = mean ΔCt value (target samples) - mean ΔCt value (control sam-
ples)]. RQ was calculated from these ΔΔCt values (RQ = 2−ΔΔCt) and used for fold change calculations. Results 
are expressed as fold changes in logarithms to base 2 (log2) of the RQ values.
Heat maps were created with the plotly and ggplot2 R packages version 3.5 (R Foundation for Statistical 
Computing, Vienna, Austria; https://www.R-project.org/).
Gene symbol Gene name Assay ID
Membrane purinergic degrading enzymes
ENTPD1/CD39 Ectonucleoside triphosphate diphosphohydrolase 1 Hs00969559_m1
ENTPD2 Ectonucleoside triphosphate diphosphohydrolase 2 Hs00993193_g1
ENTPD3 Ectonucleoside triphosphate diphosphohydrolase 3 Hs00154325_m1
ENPP1 Ectonucleotide pyrophosphatase/phosphodiesterase 1 Hs01054040_m1
NT5E/CD73 5′-nucleotidase ecto Hs04234687_m1
Soluble purinergic degrading enzyme
ADA Adenosine deaminase Hs01113256_g1
ADA receptor
DPP4/CD26 Dipeptidyl peptidase 4 Hs00897386_m1
P2 receptors
P2RX2 Purinergic receptor P2X2 Hs04176268_g1
P2RX7 Purinergic receptor P2X7 Hs00951607_m1
P2RY2 Purinergic receptor P2Y2 Hs04176264_s1
P1 receptors
ADORA1 Adenosine A1 receptor Hs00379752_m1
ADORA2A Adenosine A2a receptor Hs00169123_m1
ADORA2B Adenosine A2b receptor Hs00386497_m1
ADORA3 Adenosine A3 receptor Hs04194761_s1
Inflammatory genes
IL-13 Interleukin 13 Hs01124272_g1
IL-4 Interleukin 4 Hs00929862_m1
CCL18 C-C motif chemokine ligand 18/PARC Hs00268113_m1
Table 3. List of genes analysed in the study.
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Statistical analysis. Continuous variables were compared by Student’s t-test and expressed as mean ± standard 
deviation (SD). Qualitative variables were compared with the chi-square test. Comparisons between the groups were 
evaluated by one-way analysis of variance (ANOVA) and an overall p-value was calculated. Adjusted analyses were 
performed using unbalanced demographic variables (gender and diabetes). Statistical analysis was performed using 
IBM SPSS version 19.0 (IBM Corp., Armonk, NY, USA). A p-value less than 0.05 indicated statistical significance.
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